Plus Therapeutics (PSTV) Accumulated Expenses (2011 - 2025)
Plus Therapeutics (PSTV) reported Accumulated Expenses of $993000.0 for Q4 2025, up 7.93% year-over-year from $920000.0 in Q4 2024, and up 7.93% quarter-over-quarter from $920000.0 in Q4 2024.
Plus Therapeutics (PSTV) Accumulated Expenses (2011 - 2025) Analysis & Trends
Plus Therapeutics (PSTV) has 15 years of Accumulated Expenses data on file, last reported at $993000.0 in Q4 2025.
- Accumulated Expenses for Q4 2025 came in at $993000.0, up 7.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $993000.0 (up 7.93% YoY), and the FY2025 annual result was $993000.0, up 7.93% from the prior year.
- Accumulated Expenses improved to $993000.0 in Q4 2025 per PSTV's latest filing, from $920000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $993000.0 in Q4 2025 and troughed at $781000.0 in Q4 2021.
- A 5-year average of $934000.0 and a median of $987000.0 in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses grew 26.63% in 2022, then slipped 6.79% in 2024.
- A 5-year view of Accumulated Expenses shows it stood at $781000.0 in 2021, then grew by 26.63% to $989000.0 in 2022, then slipped by 0.2% to $987000.0 in 2023, then fell by 6.79% to $920000.0 in 2024, then rose by 7.93% to $993000.0 in 2025.
- Business Quant data shows PSTV's Accumulated Expenses at $993000.0 in Q4 2025, $920000.0 in Q4 2024, and $987000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 993,000.00 |
| Dec 31, 2024 | 920,000.00 |
| Dec 31, 2023 | 987,000.00 |
| Dec 31, 2022 | 989,000.00 |
| Dec 31, 2021 | 781,000.00 |
| Dec 31, 2020 | 738,000.00 |
| Dec 31, 2019 | 679,000.00 |
| Dec 31, 2018 | 423,000.00 |
| Dec 31, 2017 | 64,000.00 |
| Dec 31, 2016 | 989,000.00 |
| Dec 31, 2015 | 573,000.00 |
| Dec 31, 2014 | 577,000.00 |
| Dec 31, 2013 | 918,000.00 |
| Dec 31, 2012 | 846,000.00 |
| Dec 31, 2011 | 866,000.00 |